General MedicationsORALStandard
DIFLUNISAL
DIFLUNISAL
Standard Dose
250MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview DIFLUNISAL is listed in Drugs@FDA under application 202845 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient DIFLUNISAL Form and strength TABLET;ORAL - 250MG Sponsor HERITAGE PHARMA Submission history Latest submission status date: 2024-11-21 00:00:00.
Structured Monograph
Clinical summary
Approval overview DIFLUNISAL is listed in Drugs@FDA under application 202845 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient DIFLUNISAL Form and strength TABLET;ORAL - 250MG Sponsor HERITAGE PHARMA Submission history Latest submission status date: 2024-11-21 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.